All In Biotech

Drug Trial Radar · NCT05960240

Safety, Tolerability, PK & PD of AB-101 Following Oral Administration in Healthy and CHB Subjects.

A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple Dose Study Evaluating the Safety, Tolerability, PK and PD of AB-101, an Oral PD-L1 Inhibitor, in Healthy Subjects and Subjects With Chronic HBV Infection.

Last checked: Nov 19, 2026Latest source record: Apr 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 128 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

128

Actual

Start

Aug 30, 2023

Primary completion

Dec 4, 2025

Study completion Feb 9, 2026

Sponsor

Lead sponsor
Arbutus Biopharma CorporationIndustry
Sponsor type
Industry
First posted
Jul 25, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This three-part, Phase 1 protocol will be the first clinical study of AB-101. Parts 1 and 2 will be a Phase 1a SAD/MAD of AB-101 in healthy adult subjects. Part 3 will be a Phase 1b dose-ranging assessment of AB-101 in non-cirrhotic Chronic Hepatitis B (CHB) subjects.

Conditions

  • Chronic Hepatitis b

Interventions

  • AB-101Drug

    AB-101 is an oral small molecule PD-L1 checkpoint inhibitor being developed for the treatment of chronic infection with HBV in combination with other agents.

  • PlaceboDrug

    A placebo is any treatment that has no active properties, such as a sugar pill. We will use matching placebo for this study.

  • Nucleos(t)ide AnalogueDrug

    Nucleos(t)ide analogues (NUCs) are the standard and mostly lifelong treatment for chronic HBeAg-negative hepatitis B.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Parts 1 and 2: Incidence of adverse events (AEs), serious AEs (SAEs), immune related AEs (irAEs) and discontinuations due to AEs and irAEs.Time frame: [Time Frame: Up to 57 (Part 1) or 84 (Part 2) days]
  2. Part 3: Incidence of AEs, SAEs, irAEs and discontinuations due to AEs and irAEsTime frame: [Time Frame: Up to 196 days]
  3. Parts 1 and 2: Incidence of clinically significant laboratory abnormalities Parts 1 and 2: Incidence of clinically significant laboratory abnormalitiesTime frame: [Time Frame: Up to 57 (Part 1) or 84 (Part 2) days]
  4. Parts 1 and 2: Incidence of clinically significant changes in vital signs (heart rate, blood pressure, temperature, respiratory rate), physical examinations and electrocardiograms (ECGs)Time frame: [Time Frame: Up to 57 (Part 1) or 84 (Part 2) days]
  5. Part 3: Incidence of clinically significant laboratory abnormalitiesTime frame: [Time Frame: Up to 196 days]
  6. Part 3: Incidence of clinically significant changes in vital signs (heart rate, blood pressure, temperature, respiratory rate), physical examinations and electrocardiograms (ECGs)Time frame: [Time Frame: Up to 196 days]

Locations

10 sites in 7 countries. Site status is shown where the registry gives one.

  • Prince of Wales Hospital

    Hong Kong, Hong Kong, Hong Kong

  • Queen Mary Hospital - PPDS

    Hong Kong, Hong Kong, Hong Kong

  • ASST Papa Giovanni XXIII -Osepedale

    Bergamo, Italy

  • Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico

    Milan, Italy

  • Clinial Republican Hospital "Timofei Mosneaga"

    Chisinau, Moldova

  • New Zealand Clinical Research Auckland

    Grafton, Auckland, New Zealand

  • Clinical Republican Hospital "Timofei Mosneaga", ARENSIA E. M.

    Bucharest, Romania

  • National University Hospital

    Singapore, Singapore

  • Singapore General Hospital

    Singapore, Singapore

  • Municipal Non-Profit Enterprise Kyiv City Clinical Hospital No12 Executive Body of Kyiv City Council

    Kyiv, Ukraine

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.